9 results match your criteria: "Albert Einstein College of Medicine (R.B.L.[Affiliation]"
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.
Neurology
September 2024
From the Albert Einstein College of Medicine (R.B.L.), Bronx, NY; Massachusetts General Hospital (A.M.H.), Boston; AbbVie (J.Y.M., J.S., P.G., J.M.T.), Madison, NJ; AbbVie (J.H.S., K.J.-P., G.S.J.), North Chicago, IL; Department of Neurology (D.W.D.), Mayo Clinic, Scottsdale, AZ; and Atria Academy of Science and Medicine (D.W.D.), New York, NY.
Background And Objectives: Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The PRODROME trial previously demonstrated that ubrogepant treatment during prodrome prevents the onset of moderate or severe headache. In this analysis of the PRODROME trial, the benefits of ubrogepant treatment during the prodrome on patient-reported outcomes (PROs) are evaluated.
View Article and Find Full Text PDFFrequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine: A VA Nationwide Cohort Study.
Neurology
October 2022
From the VA Connecticut Healthcare System (B.T.F., K.W., A.S.G., M.S., J.J.S.), West Haven; Yeshiva University (A.S.G.), Bronx; Albert Einstein College of Medicine (R.B.L.), Bronx; Montefiore Medical Center (R.B.L.), Bronx, NY; Yale School of Medicine (B.T.F., K.W., M.S., J.J.S.), New Haven; Yale School of Public Health (K.W.), New Haven, CT; Bedford VA Medical Center (J.N.); Boston University School of Medicine (J.N.), MA; Richard L. Roudebush VA Medical Center (T.D.), Indianapolis; and Indiana University School of Medicine (T.D.), Indianapolis.
Background And Objective: To describe the relative frequency, demographics, comorbidities, and health care utilization of veterans who receive migraine care at the Veteran's Health Administration (VHA) and to evaluate differences by gender.
Methods: This study extracted data from VHA administrative sources. Veterans diagnosed with migraine by a health care provider between fiscal year 2008 and 2019 were included.
Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.
Neurology
August 2020
From the Montefiore Headache Center (R.B.L.), Albert Einstein College of Medicine (R.B.L., D.C.B.), Bronx, NY; and Teva Pharmaceutical Industries Ltd. (J.M.C., S.K.G., R.Y., P.P.Y.), West Chester, PA.
Objective: To evaluate fremanezumab quarterly or monthly vs placebo on health-related quality of life, health status, patients' global impression of change, and productivity in patients with chronic migraine (CM).
Methods: HALO CM was a double-blind, placebo-controlled trial in patients with CM. Patients were randomized 1:1:1 to treatment with fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (225 mg at baseline, weeks 4 and 8), or placebo.
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
Neurology
May 2020
From the New England Institute of Neurology and Headache (K.M.), Stamford, CT; California Medical Clinic for Headache (D.K.), Santa Monica; Biohaven Pharmaceuticals, Inc (R.C., M.L., C.M.C., V.C.), New Haven, CT; and Albert Einstein College of Medicine (R.B.L.), Bronx, NY.
Objective: To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine.
Methods: Case reports are presented of 2 patients participating in a long-term safety study of rimegepant 75 mg oral tablets for acute treatment (NCT03266588). After Food and Drug Administration approval of erenumab, both patients started subcutaneous erenumab monthly as allowed per protocol.
Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.
Neurology
December 2019
From the Albert Einstein College of Medicine (R.B.L., D.C.B.), Bronx, NY; Vedanta Research (K.M.F., M.L.R.), Chapel Hill, NC; University of Cincinnati Headache and Facial Pain Center (V.T.M.), University of Cincinnati College of Medicine, OH; CHC Group, LLC (L.B.H.), North Wales, PA; Allergan plc (A.M.A.), Irvine, CA; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), King's College, London, UK; and Department of Neurology (P.J.G.), University of California, San Francisco.
Objective: To test the hypothesis that statistically defined subgroups of migraine (based on constellations of comorbidities and concomitant conditions; henceforth comorbidities), previously identified using Chronic Migraine Epidemiology and Outcomes (CaMEO) Study data, differ in prognosis, as measured by rates of progression from episodic migraine (EM) to chronic migraine (CM).
Methods: The onset of CM was assessed up to 4 times over 12 months in individuals with EM and ≥1 comorbidity at baseline, based on constellations of comorbidities (comorbidity classes). The "fewest comorbidities" class served as reference.
Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.
Neurology
August 2016
From Jefferson Headache Center (S.D.S.), Philadelphia, PA; Carolina Headache Institute (A.H.C.), Chapel Hill, NC; Montefiore Headache Center and Albert Einstein College of Medicine (R.B.L.), Bronx, NY; Hartford HealthCare Headache Center (B.M.G.), West Hartford, CT; Clinvest Headache Care Center (R.K.C.), Springfield, MO; MedLogix Communications, LLC (S.D.), Schaumburg, IL; electroCore, LLC (K.A.S., E.J.L.), Basking Ridge, NJ; NAMSA (C.M.), Minneapolis, MN; University of California San Francisco (P.J.G.); King's College London (P.J.G.), UK; and Michigan Headache and Neurological Institute (J.R.S.), Ann Arbor. B.M.G. was affiliated with Montefiore Headache Center, Bronx, NY, at the time of study completion.
Objective: To evaluate the feasibility, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS) for the prevention of chronic migraine (CM) attacks.
Methods: In this first prospective, multicenter, double-blind, sham-controlled pilot study of nVNS in CM prophylaxis, adults with CM (≥15 headache d/mo) entered the baseline phase (1 month) and were subsequently randomized to nVNS or sham treatment (2 months) before receiving open-label nVNS treatment (6 months). The primary endpoints were safety and tolerability.
The migraine postdrome: An electronic diary study.
Neurology
July 2016
From the Department of Neurology (N.J.G.), Royal United Hospital, Bath, UK; Albert Einstein College of Medicine (R.B.L.), New York, NY; Thomas Jefferson University (S.D.S.), Philadelphia, PA; Danish Headache Centre (J.O.), Glostrup Hospital, Denmark; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), King's College London, UK; and Department of Neurology (P.J.G.), University of California, San Francisco.
Objective: To report migraine postdrome symptoms in patients who report nonheadache symptoms as part of their attacks.
Methods: A prospective daily electronic diary study was conducted over 3 months in 120 patients with migraine. Nonheadache symptoms before, during, and after headache were collected on a daily basis.
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.
Neurology
February 2015
From Albert Einstein College of Medicine (R.B.L., D.S., D.C.B.), Bronx; Montefiore Headache Center (R.B.L., D.C.B.), Bronx, NY; Vedanta Research (K.M.F., D.S., M.L.R.), Chapel Hill, NC; and Headache Care Center (R.C.), Springfield, MO.
Objective: To test the hypothesis that ineffective acute treatment of episodic migraine (EM) is associated with an increased risk for the subsequent onset of chronic migraine (CM).
Methods: In the American Migraine Prevalence and Prevention Study, respondents with EM in 2006 who completed the Migraine Treatment Optimization Questionnaire (mTOQ-4) and provided outcome data in 2007 were eligible for analyses. The mTOQ-4 is a validated questionnaire that assesses treatment efficacy based on 4 aspects of response to acute treatment.
Migraine prevalence, socioeconomic status, and social causation.
Neurology
September 2013
From Sutter Health (W.F.S.), Concord, CA; University of Pennsylvania (J.R.), Philadelphia; and Albert Einstein College of Medicine (R.B.L.), Bronx, NY.
Objective: To determine whether the known higher prevalence of migraine in lower household (HH) income groups is explained by a higher incidence rate or a lower remission rate.
Methods: We used data from the American Migraine Prevalence and Prevention Study, a US national sample of 132,674 females (with a 64.3% response rate) and 124,665 males (with a 62.